Comparative in vitro biological activity of trastuzumab-associated PLGA nanoparticle formulations in gastric cancer cell models

Background Trastuzumab is an anti-HER2 monoclonal antibody used in HER2-positive gastric cancer. PLGA-based nanoparticle systems may modulate antibody presentation and availability within engineered delivery platforms. Methods The in vitro effects of free trastuzumab and trastuzumab-associated PLGA nanoparticles were evaluated in NCI-N87 and AGS gastric cancer cell models. Cell viability and cytotoxicity were assessed using MTT and lactate dehydrogenase (LDH) release assays, respectively. Trastuzumab was associated with PLGA nanoparticles in three configurations: internally associated (IN), surface-associated (OUT), and combined internal/surface-associated (IN + OUT). Peripheral blood mononuclear cells (PBMCs) were included as effector cells in LDH co-culture experiments. Results Empty PLGA nanoparticles did not significantly reduce NCI-N87 metabolic viability in the MTT assay, whereas LDH release was detectable under PBMC co-culture conditions. In NCI-N87 cells, trastuzumab-associated formulations induced greater in vitro effects than control conditions, with a formulation-associated pattern. The combined IN + OUT configuration showed the strongest activity, followed by OUT, whereas IN displayed comparatively lower activity. In contrast, AGS cells showed statistically detectable but biologically modest responses, with cell viability remaining consistently high and LDH release showing lower, less differentiated changes. Conclusion The investigated trastuzumab-associated PLGA nanoparticle formulations exhibited differential in vitro biological responses in gastric cancer cell models, with the combined internal/surface-associated formulation showing the most pronounced effects in NCI-N87 cells. However, the experimental design does not establish whether these differences are specifically attributable to antibody spatial presentation, HER2-dependent mechanisms, or immune-mediated cytotoxicity. These preliminary findings support further comparative and mechanistic investigations of antibody-associated PLGA nanocarriers.

Authors

Institutions

Publication Details

Journal
Frontiers in Drug Delivery
Published
2026-11-19
DOI
https://doi.org/10.3389/fddev.2026.1990262
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparative in vitro biological activity of trastuzumab-associated PLGA nanoparticle formulations in gastric cancer cell models

Piercarmine Porcaro, Pasquale Vito, Gaetano Cardinale, Serena Voccola et al.
Frontiers in Drug Delivery
Nanoparticle-Based Drug Delivery
article

Comparative in vitro biological activity of trastuzumab-associated PLGA nanoparticle formulations in gastric cancer cell models

Piercarmine Porcaro, Pasquale Vito, Gaetano Cardinale, Serena Voccola, Floriana Porcaro
article en

Abstract

Background Trastuzumab is an anti-HER2 monoclonal antibody used in HER2-positive gastric cancer. PLGA-based nanoparticle systems may modulate antibody presentation and availability within engineered delivery platforms. Methods The in vitro effects of free trastuzumab and trastuzumab-associated PLGA nanoparticles were evaluated in NCI-N87 and AGS gastric cancer cell models. Cell viability and cytotoxicity were assessed using MTT and lactate dehydrogenase (LDH) release assays, respectively. Trastuzumab was associated with PLGA nanoparticles in three configurations: internally associated (IN), surface-associated (OUT), and combined internal/surface-associated (IN + OUT). Peripheral blood mononuclear cells (PBMCs) were included as effector cells in LDH co-culture experiments. Results Empty PLGA nanoparticles did not significantly reduce NCI-N87 metabolic viability in the MTT assay, whereas LDH release was detectable under PBMC co-culture conditions. In NCI-N87 cells, trastuzumab-associated formulations induced greater in vitro effects than control conditions, with a formulation-associated pattern. The combined IN + OUT configuration showed the strongest activity, followed by OUT, whereas IN displayed comparatively lower activity. In contrast, AGS cells showed statistically detectable but biologically modest responses, with cell viability remaining consistently high and LDH release showing lower, less differentiated changes. Conclusion The investigated trastuzumab-associated PLGA nanoparticle formulations exhibited differential in vitro biological responses in gastric cancer cell models, with the combined internal/surface-associated formulation showing the most pronounced effects in NCI-N87 cells. However, the experimental design does not establish whether these differences are specifically attributable to antibody spatial presentation, HER2-dependent mechanisms, or immune-mediated cytotoxicity. These preliminary findings support further comparative and mechanistic investigations of antibody-associated PLGA nanocarriers.

Frontiers in Drug DeliveryVol. 6
University of Sannio (IT)
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon